*
*
Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable
54321NA
The skills learned in this CME course enhanced my professional competence.
The skills learned in this CME course will be applied in the treatment of my patients.
*
5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence NA|Not applicable to my practice
54321
Properly diagnose and manage primary and metastatic brain tumors.
Apply targeted agents, immunotherapy and novel technologies to treat gliomas.
*
Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied
54321
This House Believes There Is No Role for Dose-Escalation for Glioblastoma - Michelle Kim, M.D.
Targeting Androgen Receptors in Glioblastoma - Chi (Kevin) Zhang, M.D.
Exploring Glutaminase Inhibition in Glioma - Sani H. Kizilbash, M.D.
Vaccines Therapy for Glioblastomas - Manmeet Ahluwalia, M.D., MBA, FASCO
Surveillance vs. SRS for Asymptomatic Vestibular Schwannomas - Pablo Recinos, M.D. and Paul D. Brown, M.D.
Surgical Advances for Skull Base Tumors - Christina Jackson, M.D.
Radiotherapy Advances for Skull Base Tumors - Joshua D. Palmer, M.D.
Novel Systemic Therapies for Recurrent Meningiomas - Yazmin Odia, M.D., M.S., FAAN
Systemic Therapy vs. Craniospinal Irradiation for Leptomeningeal Disease - Adrienne Boire, M.D. and Jonathan T. Yang, M.D., Ph.D.
SRS vs. WBRT for Multiple (>10) Brain Metastases - Paul D. Brown, M.D. and Rupesh Kotecha, M.D.
Surgery vs. SRS for Meningiomas - Evan Bander, M.D. and Pablo Recinos, M.D.
Novocure METIS - Minesh Mehta, M.D., FASTRO 
Pediatric Brain Tumor - John T. Lucas Jr., M.S., M.D.
Development Considerations for CAR T Cell Therapy for GBM - Steven Bagley, M.D. 
*
*
*
*
*
*
*
*